Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma.

Cancer letters·2026

Same author

Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia.

Science translational medicine·2024

Same author

Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing.

Nature communications·2024

Same author

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche.

Nature communications·2024

Same author

Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.

Nature communications·2023

Same author

Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells.

EMBO reports·2023

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Targeting chronic myeloid leukemia stem cells.

G Vignir Helgason¹, Graham A R Young, Tessa L Holyoake

¹Paul O'Gorman Leukaemia Research Centre, Faculty of Medicine, Gartnavel General Hospital, University of Glasgow, Glasgow, UK. gvh3y@clinmed.gla.ac.uk

Current Hematologic Malignancy Reports

|April 29, 2010

Summary

Chronic myeloid leukemia (CML) originates from the Philadelphia chromosome and Bcr-Abl oncogene. Novel strategies are needed to eradicate persistent CML stem cells resistant to tyrosine kinase inhibitors.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Chronic myeloid leukemia (CML) is a stem cell malignancy driven by the Philadelphia chromosome and Bcr-Abl oncogene.
Targeted therapies like imatinib mesylate have improved CML treatment but face challenges with residual disease and resistance.
Tumor-initiating cells in CML are implicated in disease persistence and resistance to therapy.

Purpose of the Study:

To review recent findings on novel strategies for CML eradication.
To discuss the challenges posed by persistent CML stem cells.
To highlight the importance of targeting stem cells for achieving a cure.

Main Methods:

Review of recent scientific literature on CML pathogenesis and treatment.
Analysis of data regarding residual disease and stem cell persistence.
Discussion of emerging therapeutic approaches targeting CML stem cells.

Main Results:

Residual CML disease is concentrated in the stem cell compartment.
These stem cells can persist for years despite achieving complete cytogenetic response.
Resistance to tyrosine kinase inhibitors is a significant clinical challenge.

Conclusions:

Eliminating CML stem cells is crucial for achieving a complete cure.
Novel therapeutic strategies are required to overcome resistance and eradicate residual disease.
Further research into targeting tumor-initiating cells holds promise for CML treatment.